Request for Covid-19 Impact Assessment of this Report
The United States Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market, reaching US$ million by the year 2028. As for the Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) players cover BMS, Generium, Novo Nordisk, and Shire (Baxter), etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
60 KIU
50 KIU
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Bleeding
Surgery Assisted
Glanzmann Plateletasthenia
Hemophilia B
Hemophilia A
Head Trauma
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
BMS
Generium
Novo Nordisk
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Suzhou Alphamab
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Country/Region, 2017, 2022 & 2028
2.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Segment by Type
2.2.1 60 KIU
2.2.2 50 KIU
2.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
2.3.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2017-2022)
2.3.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue and Market Share by Type (2017-2022)
2.3.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Type (2017-2022)
2.4 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Segment by Application
2.4.1 Bleeding
2.4.2 Surgery Assisted
2.4.3 Glanzmann Plateletasthenia
2.4.4 Hemophilia B
2.4.5 Hemophilia A
2.4.6 Head Trauma
2.4.7 Others
2.5 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
2.5.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Market Share by Application (2017-2022)
2.5.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue and Market Share by Application (2017-2022)
2.5.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Application (2017-2022)
3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Company
3.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Breakdown Data by Company
3.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales by Company (2020-2022)
3.1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Company (2020-2022)
3.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Revenue by Company (2020-2022)
3.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Company (2020-2022)
3.2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Company (2020-2022)
3.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Company
3.4 Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Location Distribution
3.4.2 Players Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Geographic Region
4.1 World Historic Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Geographic Region (2017-2022)
4.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Revenue by Geographic Region
4.2 World Historic Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Country/Region (2017-2022)
4.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales by Country/Region (2017-2022)
4.2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Revenue by Country/Region
4.3 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth
4.4 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth
4.5 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth
4.6 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth
5 Americas
5.1 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country
5.1.1 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2017-2022)
5.1.2 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2017-2022)
5.2 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
5.3 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region
6.1.1 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2017-2022)
6.1.2 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region (2017-2022)
6.2 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
6.3 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Country
7.1.1 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2017-2022)
7.1.2 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2017-2022)
7.2 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
7.3 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Country
8.1.1 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2017-2022)
8.1.2 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2017-2022)
8.2 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
8.3 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
10.3 Manufacturing Process Analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
10.4 Industry Chain Structure of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Distributors
11.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Customer
12 World Forecast Review for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Geographic Region
12.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size Forecast by Region
12.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Forecast by Region (2023-2028)
12.1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Forecast by Type
12.7 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Forecast by Application
13 Key Players Analysis
13.1 BMS
13.1.1 BMS Company Information
13.1.2 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.1.3 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 BMS Main Business Overview
13.1.5 BMS Latest Developments
13.2 Generium
13.2.1 Generium Company Information
13.2.2 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.2.3 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Generium Main Business Overview
13.2.5 Generium Latest Developments
13.3 Novo Nordisk
13.3.1 Novo Nordisk Company Information
13.3.2 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.3.3 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Novo Nordisk Main Business Overview
13.3.5 Novo Nordisk Latest Developments
13.4 Shire (Baxter)
13.4.1 Shire (Baxter) Company Information
13.4.2 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.4.3 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Shire (Baxter) Main Business Overview
13.4.5 Shire (Baxter) Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.5.3 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 CSL
13.6.1 CSL Company Information
13.6.2 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.6.3 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 CSL Main Business Overview
13.6.5 CSL Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.7.3 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 Grifols
13.8.1 Grifols Company Information
13.8.2 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.8.3 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Grifols Main Business Overview
13.8.5 Grifols Latest Developments
13.9 Biogen
13.9.1 Biogen Company Information
13.9.2 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.9.3 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Biogen Main Business Overview
13.9.5 Biogen Latest Developments
13.10 Octapharma
13.10.1 Octapharma Company Information
13.10.2 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.10.3 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Octapharma Main Business Overview
13.10.5 Octapharma Latest Developments
13.11 NovoNordisk
13.11.1 NovoNordisk Company Information
13.11.2 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.11.3 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 NovoNordisk Main Business Overview
13.11.5 NovoNordisk Latest Developments
13.12 Greencross
13.12.1 Greencross Company Information
13.12.2 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.12.3 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Greencross Main Business Overview
13.12.5 Greencross Latest Developments
13.13 Kedrion
13.13.1 Kedrion Company Information
13.13.2 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.13.3 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Kedrion Main Business Overview
13.13.5 Kedrion Latest Developments
13.14 BPL
13.14.1 BPL Company Information
13.14.2 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.14.3 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 BPL Main Business Overview
13.14.5 BPL Latest Developments
13.15 Hualan Bio
13.15.1 Hualan Bio Company Information
13.15.2 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.15.3 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Hualan Bio Main Business Overview
13.15.5 Hualan Bio Latest Developments
13.16 RAAS
13.16.1 RAAS Company Information
13.16.2 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.16.3 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 RAAS Main Business Overview
13.16.5 RAAS Latest Developments
13.17 Suzhou Alphamab
13.17.1 Suzhou Alphamab Company Information
13.17.2 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
13.17.3 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2020-2022)
13.17.4 Suzhou Alphamab Main Business Overview
13.17.5 Suzhou Alphamab Latest Developments
14 Research Findings and Conclusion
Table 1. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of 60 KIU
Table 4. Major Players of 50 KIU
Table 5. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2017-2022) & (K Units)
Table 6. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2017-2022)
Table 7. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Type (2017-2022) & ($ million)
Table 8. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Type (2017-2022)
Table 9. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Type (2017-2022) & (US$/Unit)
Table 10. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2017-2022) & (K Units)
Table 11. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2017-2022)
Table 12. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Application (2017-2022)
Table 13. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Application (2017-2022)
Table 14. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Application (2017-2022) & (US$/Unit)
Table 15. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Company (2020-2022) & (K Units)
Table 16. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Company (2020-2022)
Table 17. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Company (2020-2022)
Table 19. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Company (2020-2022) & (US$/Unit)
Table 20. Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Producing Area Distribution and Sales Area
Table 21. Players Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Products Offered
Table 22. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Geographic Region (2017-2022) & (K Units)
Table 26. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share Geographic Region (2017-2022)
Table 27. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country/Region (2017-2022) & (K Units)
Table 30. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country/Region (2017-2022)
Table 31. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2017-2022) & (K Units)
Table 34. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country (2017-2022)
Table 35. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country (2017-2022)
Table 37. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2017-2022) & (K Units)
Table 38. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2017-2022)
Table 39. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2017-2022) & (K Units)
Table 40. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2017-2022)
Table 41. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2017-2022) & (K Units)
Table 42. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Region (2017-2022)
Table 43. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Region (2017-2022)
Table 45. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2017-2022) & (K Units)
Table 46. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2017-2022)
Table 47. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2017-2022) & (K Units)
Table 48. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2017-2022)
Table 49. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2017-2022) & (K Units)
Table 50. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country (2017-2022)
Table 51. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country (2017-2022)
Table 53. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2017-2022) & (K Units)
Table 54. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2017-2022)
Table 55. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2017-2022) & (K Units)
Table 56. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2017-2022) & (K Units)
Table 58. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2017-2022) & (K Units)
Table 62. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2017-2022) & (K Units)
Table 64. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Table 66. Key Market Challenges & Risks of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Table 67. Key Industry Trends of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Table 68. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Distributors List
Table 71. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Customer List
Table 72. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Region (2023-2028) & (K Units)
Table 73. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Forecast by Region
Table 74. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Country (2023-2028) & (K Units)
Table 77. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Region (2023-2028) & (K Units)
Table 79. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Type (2023-2028) & (K Units)
Table 85. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Application (2023-2028) & (K Units)
Table 89. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share Forecast by Application (2023-2028)
Table 92. BMS Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 93. BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 94. BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 95. BMS Main Business
Table 96. BMS Latest Developments
Table 97. Generium Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 98. Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 99. Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 100. Generium Main Business
Table 101. Generium Latest Developments
Table 102. Novo Nordisk Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 103. Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 104. Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 105. Novo Nordisk Main Business
Table 106. Novo Nordisk Latest Developments
Table 107. Shire (Baxter) Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 108. Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 109. Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 110. Shire (Baxter) Main Business
Table 111. Shire (Baxter) Latest Developments
Table 112. Bayer Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 113. Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 114. Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 115. Bayer Main Business
Table 116. Bayer Latest Developments
Table 117. CSL Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 118. CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 119. CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 120. CSL Main Business
Table 121. CSL Latest Developments
Table 122. Pfizer Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 123. Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 124. Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 125. Pfizer Main Business
Table 126. Pfizer Latest Developments
Table 127. Grifols Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 128. Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 129. Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 130. Grifols Main Business
Table 131. Grifols Latest Developments
Table 132. Biogen Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 133. Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 134. Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 135. Biogen Main Business
Table 136. Biogen Latest Developments
Table 137. Octapharma Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 138. Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 139. Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 140. Octapharma Main Business
Table 141. Octapharma Latest Developments
Table 142. NovoNordisk Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 143. NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 144. NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 145. NovoNordisk Main Business
Table 146. NovoNordisk Latest Developments
Table 147. Greencross Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 148. Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 149. Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 150. Greencross Main Business
Table 151. Greencross Latest Developments
Table 152. Kedrion Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 153. Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 154. Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 155. Kedrion Main Business
Table 156. Kedrion Latest Developments
Table 157. BPL Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 158. BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 159. BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 160. BPL Main Business
Table 161. BPL Latest Developments
Table 162. Hualan Bio Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 163. Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 164. Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 165. Hualan Bio Main Business
Table 166. Hualan Bio Latest Developments
Table 167. RAAS Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 168. RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 169. RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 170. RAAS Main Business
Table 171. RAAS Latest Developments
Table 172. Suzhou Alphamab Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 173. Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offered
Table 174. Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 175. Suzhou Alphamab Main Business
Table 176. Suzhou Alphamab Latest Developments
List of Figures
Figure 1. Picture of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Figure 2. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of 60 KIU
Figure 10. Product Picture of 50 KIU
Figure 11. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type in 2021
Figure 12. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Type (2017-2022)
Figure 13. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Bleeding
Figure 14. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Bleeding (2017-2022) & (K Units)
Figure 15. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Surgery Assisted
Figure 16. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Surgery Assisted (2017-2022) & (K Units)
Figure 17. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Glanzmann Plateletasthenia
Figure 18. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Glanzmann Plateletasthenia (2017-2022) & (K Units)
Figure 19. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Hemophilia B
Figure 20. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Hemophilia B (2017-2022) & (K Units)
Figure 21. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Hemophilia A
Figure 22. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Hemophilia A (2017-2022) & (K Units)
Figure 23. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Head Trauma
Figure 24. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Head Trauma (2017-2022) & (K Units)
Figure 25. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Others
Figure 26. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Others (2017-2022) & (K Units)
Figure 27. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2017-2022)
Figure 28. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Application in 2021
Figure 29. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market by Company in 2021 ($ Million)
Figure 30. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Company in 2021
Figure 31. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Geographic Region (2017-2022)
Figure 32. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Geographic Region in 2021
Figure 33. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Region (2017-2022)
Figure 34. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country/Region in 2021
Figure 35. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales 2017-2022 (K Units)
Figure 36. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue 2017-2022 ($ Millions)
Figure 37. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales 2017-2022 (K Units)
Figure 38. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue 2017-2022 ($ Millions)
Figure 39. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales 2017-2022 (K Units)
Figure 40. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue 2017-2022 ($ Millions)
Figure 41. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales 2017-2022 (K Units)
Figure 42. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue 2017-2022 ($ Millions)
Figure 43. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country in 2021
Figure 44. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country in 2021
Figure 45. United States Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 46. Canada Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 47. Mexico Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 48. Brazil Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 49. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Region in 2021
Figure 50. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Regions in 2021
Figure 51. China Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 52. Japan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 53. South Korea Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 54. Southeast Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 55. India Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 56. Australia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 57. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country in 2021
Figure 58. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country in 2021
Figure 59. Germany Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 60. France Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 61. UK Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 62. Italy Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 63. Russia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 64. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country in 2021
Figure 65. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country in 2021
Figure 66. Egypt Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 67. South Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 68. Israel Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 69. Turkey Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 70. GCC Country Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2017-2022 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) in 2021
Figure 72. Manufacturing Process Analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Figure 73. Industry Chain Structure of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Figure 74. Channels of Distribution
Figure 75. Distributors Profiles
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...